首页> 外文OA文献 >Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
【2h】

Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

机译:组织型纤溶酶原激活物及其丝氨酸蛋白酶抑制剂抑制剂纤溶酶原激活物抑制剂1型的复合物通过低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体内化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tissue-type plasminogen activator and urokinase are serine proteases secreted by many cell types that participate in biological processes, such as tissue restructuring, cell migration, and tumor metastasis. Clinically, these proteases are used to dissolve coronary fibrin clots that are the proximal causes of acute myocardial infarction. In vivo, the activity of these enzymes is controlled by plasminogen-activator inhibitors, members of the serpin family of protease inhibitors. This study shows that tissue-type plasminogen activator-inhibitor complexes bind in solution to low density lipoprotein receptor-related protein (LRP), a large heterodimeric ubiquitous membrane receptor. In cultured cells, endocytosis and degradation of these complexes is reduced by polyclonal antibodies directed against LRP and inhibited by a M(r) 39,000 protein that binds to LRP and inhibits its interaction with previously known ligands, including apolipoprotein E and alpha 2-macroglobulin. We propose a role for LRP in the clearance of plasminogen activator-inhibitor complexes that is analogous to its function in the endocytosis of alpha 2-macroglobulin-protease complexes.
机译:组织型纤溶酶原激活剂和尿激酶是由参与生物过程(例如组织重组,细胞迁移和肿瘤转移)的许多细胞类型分泌的丝氨酸蛋白酶。在临床上,这些蛋白酶可用于溶解冠状血纤蛋白凝块,后者是急性心肌梗死的近因。在体内,这些酶的活性由纤溶酶原激活剂抑制剂(蛋白酶抑制剂的丝氨酸蛋白酶抑制剂家族的成员)控制。这项研究表明,组织型纤溶酶原激活剂-抑制剂复合物在溶液中与低密度脂蛋白受体相关蛋白(LRP)结合,LRP是一种大的异二聚体遍在膜受体。在培养的细胞中,这些复合物的内吞作用和降解被针对LRP的多克隆抗体减少,并被M(r)39,000蛋白抑制,该蛋白与LRP结合并抑制其与先前已知的配体(包括载脂蛋白E和α2-巨球蛋白)的相互作用。我们建议LRP在清除纤溶酶原激活剂-抑制剂复合物中的作用,类似于其在α2-巨球蛋白-蛋白酶复合物内吞作用中的功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号